Glaxo seeks Japan marketing OK for breast cancer pill Tykerb |
|
|
|
Published
:
Mon, 02 Apr 2007 11:17
|
LONDON (AFX) - GlaxoSmithKline PLC has submitted breast cancer pill Tykerb to Japanese medicine regulators for marketing approval.The company is seeking approval as both monotherapy and combination treatment with chemotherapy agent capecitabine for patients with advanced or metastatic HER2 positive breast cancer, in women who have received prior therapy.Tykerb was approved in the US on March 13, and is awaiting a green light in the EU and other countries.amy.brown@thomson.comab/sljCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1617.01 |
+17.95 (
1.13 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Glaxo's Tykerb approved by US FDA for advanced, metastatic breast cancer 